2024
The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis G, Correll C, Agorastos A, Sanchez A, Erzin G, Grigoras R, Benussi M, Gondek T, Guloksuz S, Højlund M, Jerotic S, Kilic O, Metaj E, Sidhu D, Skandali N, Skuhareuski A, Tveito M, Wolthusen R, Communication and Publications E, Chumakov E, de Filippis R. The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. The World Journal Of Biological Psychiatry 2024, 25: 342-351. PMID: 38905131, DOI: 10.1080/15622975.2024.2367138.Peer-Reviewed Original ResearchConceptsEuropean Psychiatric AssociationAntipsychotic treatmentPsychiatrists' attitudesTherapeutic drug monitoringEarly-career psychiatristsExploratory factor analysisBenefit of therapeutic drug monitoringPsychiatric AssociationAntipsychoticsNegative expectationsAssociated with frequencyTDM useDrug monitoringTherapeutic drug monitoring useFactor analysisBeliefs of patientsHigh-income countriesLow-/middle-income countriesResponse varianceClinical benefitClozapineOutpatient settingLinear regression analysisClinical settingPsychiatrists
2023
Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly intervention
2019
Organization framework and preliminary findings from the Athens First‐Episode Psychosis Research Study
Xenaki L, Kollias C, Stefanatou P, Ralli I, Soldatos R, Dimitrakopoulos S, Hatzimanolis A, Triantafyllou T, Kosteletos I, Vlachos I, Selakovic M, Foteli S, Mantonakis L, Ermiliou V, Voulgaraki M, Psarra E, Gülöksüz S, van Os J, Stefanis N. Organization framework and preliminary findings from the Athens First‐Episode Psychosis Research Study. Early Intervention In Psychiatry 2019, 14: 343-355. PMID: 31402581, DOI: 10.1111/eip.12865.Peer-Reviewed Original ResearchConceptsRisk factorsMild functional improvementLongitudinal cohort studySymptom severity criteriaPoor cognitive performanceOutcome of psychosisPreliminary findingsPatients 16Cohort studyAntipsychotic treatmentClinical pictureFEP patientsClinical managementFunctional improvementFamily historyEmergency unitBaseline presentationSeverity criteriaPsychiatric hospitalPsychotic disordersClinical InterviewDrug usePotential associationGene-environment interaction studiesBiochemical parameters
2012
Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees